DKDavid J. Konieczkowski

David J. Konieczkowski

*This is an algorithmically generated author record based on publicly available information.

David J. Konieczkowski has a total of 77 co-authors. Here are the top co-authors by number of shared publications:

  • Emile Gogineni

    Department of Radiation Oncology, The James Cancer Hospital/Wexner Medical Center, The Ohio State University, Columbus, OH 43210, USA

    4 shared publications
  • John Grecula

    Department of Radiation Oncology, The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University Comprehensive Cancer Center, Columbus, OH

    4 shared publications
  • Marcelo Bonomi

    Department of Medical Oncology, The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University Comprehensive Cancer Center, Columbus, OH

    4 shared publications
  • Priyanka Bhateja

    Department of Medical Oncology, The James Cancer Hospital/Wexner Medical Center, The Ohio State University, Columbus, OH 43210, USA

    4 shared publications
  • Sachin R. Jhawar

    Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, USA

    4 shared publications
  • Adriano Piris

    Mihm Cutaneous Pathology Consultative Service Boston Massachusetts USA

    3 shared publications

Latest Publications

  • Open Access

    GemSarc: A Novel Predictive Gene Signature for Gemcitabine Efficacy in Advanced Bone and Soft Tissue Sarcomas

    by Ankur Sheel, Erin Fetzer, Yue Yu, Swati Satturwar, Raven Vella, James L. Chen, Valerie P. Grignol, Joal D. Beane, Marium Husain, Gabriel Tinoco, et al.

    Purpose: There are no validated predictive biomarkers for chemotherapy response in advanced soft-tissue sarcoma. We sought to develop and validate an RNA-based gene signature predictive of gemcitabine response. Methods: Patients treated with gemcitabine-based chemotherapy were identified from The Ohio State University (OSU) Sarcoma Registry (ClinicalTrials.gov identifier: NCT02677961 ). Responders were defined as patients with a time to gemcitabine discontinuation greater than the cohort median, based on RECIST-defined progression. Gene expression from Tempus RNA sequencing data was correlated with gemcitabine half maximal inhibitory concentration from sarcoma cell lines to identify predictive transcripts. Differentially expressed genes between responders and nonresponders were intersected, and a random forest regression model was trained to generate the GemSarc score. The model was externally validated using Oncology Research Information Exchange Network (ORIEN) and Total Cancer Care (TCC) data sets. Results: Thirty-one patients met inclusion criteria. Unsupervised clustering revealed three transcriptomic subgroups, with prolonged duration of therapy in clusters enriched for DNA replication and repair pathways. The GemSarc model identified 19 genes that predicted gemcitabine sensitivity. High GemSarc scores were associated with improved clinical benefit in the OSU discovery cohort (hazard ratio [HR], 0.23 [95% CI, 0.08 to 0.66]), with consistent validation in two independent cohorts (ORIEN: HR, 0.30; TCC: HR, 0.17). The model also demonstrated strong discriminatory performance, with AUCs of 0.88 and 0.79 in the ORIEN and TCC cohorts, respectively. GemSarc did not predict overall survival or progression-free survival in patients with sarcoma from The Cancer Genome Atlas data. GemSarc also failed to identify responders to other cytotoxic agents (AUC <0.63). Conclusion: GemSarc is a validated RNA-based predictive biomarker that identifies patients with advanced sarcomas likely to benefit from gemcitabine-based therapy. Its implementation may optimize patient selection and guide biomarker-driven clinical trials in sarcoma.

  • Open Access

    Unplanned Hospitalization and Percutaneous Endoscopic Gastrostomy Tube Use for Head and Neck Cancer

    by Sung Jun Ma, Daniel Alvarez, Krithik Tella, Jacob Wells, Alec Kotler, Darien Reed, Kevin Agner, Om Desai, Matthew Nguyen, Andrew Koempel, et al.

    PURPOSE: There is a heterogeneous practice pattern in prophylactic percutaneous endoscopic gastrostomy (PEG) tube placement, and it is unclear whether increased hospitalization is driven by those with versus without prophylactic PEG tube. To address this knowledge gap, we performed an observational cohort study to evaluate the association of PEG tube with hospitalization and other clinical outcomes. METHODS: Our single-institution database was queried for patients with nonmetastatic head and neck cancer diagnosed between October 2011 and December 2023 who received definitive radiation or chemoradiation. Fine-Gray multivariable analysis (MVA) was used for time to first hospitalization and oncologic outcomes, whereas Cox MVA was used for survival outcomes. Bonferroni correction was used for multiple comparisons. RESULTS: A total of 560 patients were identified. The median follow-up was 44.9 months. Overall, 249 (44.5%) patients were hospitalized at least once. The most common reason for hospitalization was failure to thrive (n = 192 [33.9%]). When compared with prophylactic PEG tube, no PEG tube was associated with less hospitalization (adjusted hazard ratio [aHR], 0.64 [95% CI, 0.45 to 0.91]; P = .01), but not therapeutic PEG tube (aHR, 1.16 [95% CI, 0.84 to 1.59]; P = .38). There was no statistical significance in survival and oncologic outcomes among these groups. CONCLUSION: Our study suggested that nearly half of the patients were hospitalized at least once, and the most common reason was failure to thrive. Those who never had PEG tube had the lowest hospitalization rate, whereas prophylactic PEG tube was not associated with less hospitalization compared with those with therapeutic PEG tube.

  • Open Access

    Association of Systemic Inflammation Response Index With Long-Term Outcomes in Patients With Head and Neck Cancer Receiving Definitive Chemoradiation

    by Sung Jun Ma, Andrew Koempel, Krithik Tella, Daniel Alvarez, Darien Reed, Kevin E. Agner, Alec Kotler, Jacob Wells, Om Desai, Matthew Nguyen, et al.

    PURPOSE: Systemic inflammation is an important factor for carcinogenesis and tumor progression. Systemic Inflammation Response Index (SIRI) was suggested as one of the peripheral blood biomarkers to assess the magnitude of inflammation. Herein, we aimed to evaluate the prognostic value of SIRI in head and neck cancer. METHODS: A single-institution database at a comprehensive cancer center was queried for patients with nonmetastatic head and neck cancer who underwent definitive chemoradiation between December 2011 and February 2024 with SIRI available for analysis. With the top quartile as a reference to evaluate high versus low SIRI, logistic multivariable analysis (MVA) was performed to identify variables associated with high SIRI. Cox MVA was performed to evaluate survival. Interaction term analysis was performed to evaluate whether there is a heterogeneous association of SIRI with outcomes stratified by p16 status. RESULTS: A total of 638 patients met our criteria. The median follow-up was 45.9 months (95% CI, 44.4 to 47.7). Using the top quartile cutoff of 3.22 for SIRI, those who were male, underweight, had poor performance status, and had advanced T staging were more likely to have high SIRI, whereas those with other racial background, p16-positive, and larynx primary site were less likely to have high SIRI. Those with high SIRI had worse overall survival (OS; adjusted hazard ratio [aHR], 1.59 [95% CI, 1.15 to 2.25], P = .008), but not PFS (aHR, 1.18 [95% CI, 0.86 to 1.61], P = .320). Interaction term analysis did not reach statistical significance ( P interaction = .75 for OS, 0.84 for PFS). CONCLUSION: Elevated SIRI was an independent, adverse prognostic factor for survival without heterogeneous association with outcomes based on p16 status. Further validation of SIRI would be warranted in future studies.


  • Long-Term Outcomes of Weekly Cisplatin Versus Carboplatin and Paclitaxel for Head and Neck Cancer

    by Sung Jun Ma, Kevin E. Agner, Andrew Koempel, Krithik Tella, Daniel Alvarez, Alec Kotler, Jacob Wells, Darien Reed, Om Desai, Matthew Nguyen, et al.

    PURPOSE: National Comprehensive Cancer Network guidelines recommend weekly cisplatin and weekly carboplatin with paclitaxel as alternative concurrent systemic therapy regimens among patients with head and neck cancer undergoing definitive chemoradiation. However, there is a paucity of literature comparing outcomes with these two regimens. We performed an observational cohort study of patients with head and neck cancer treated with definitive chemoradiation receiving either cisplatin or carboplatin with paclitaxel. METHODS: A single-institution database was queried for patients with head and neck cancer diagnosed between October 2011 and December 2023 who underwent chemoradiation with either once a week cisplatin (40 mg/m 2 ) or once a week carboplatin (AUC 1) with paclitaxel (30 mg/m 2 ). Cox multivariable analysis (MVA), Kaplan-Meier, Fine-Gray MVA, logistic MVA, and propensity score matching were performed to evaluate treatment outcomes. RESULTS: A total of 488 patients were identified. Median follow-up was 43.1 months (95% CI, 41.0 to 45.4). The majority of patients received at least five cycles. Those with older age, former smoking history, and worse performance status were more likely to undergo carboplatin and paclitaxel. Carboplatin and paclitaxel were associated with no statistically significant overall survival (adjusted hazards ratio [aHR], 1.12 [95% CI, 0.69 to 1.82]; P = .64), progression-free survival (aHR, 1.45 [95% CI, 0.96 to 2.19]; P = .08), locoregional failure (aHR, 1.91 [95% CI, 0.85 to 4.32]; P = .12), and distant failure (aHR, 1.33 [95% CI, 0.70 to 2.54]; P = .39) compared with cisplatin. Similar findings were noted on 109 matched pairs as well as subgroups stratified by p16 status. CONCLUSION: Our study suggested that those treated with weekly carboplatin and paclitaxel had no statistically significant survival and tumor control outcomes compared with those with weekly cisplatin. Older age and poor performance status were independently associated with the receipt of weekly carboplatin and paclitaxel.

  • Open Access

    Predictors of brachial plexopathy following head and neck reirradiation

    by Khaled Dibs, Emile Gogineni, Eric Cochran, Joshua Palmer, Sachin M. Jhawar, Sujith Baliga, Darrion Mitchell, John Grecula, Marcelo Bonomi, Priyanka Bhateja, et al.

  • Open Access

    Supplementary Materials and Methods from A Melanoma Cell State Distinction Influences Sensitivity to MAPK Pathway Inhibitors

    by David J. Konieczkowski, Cory M. Johannessen, Omar Abudayyeh, Jong Wook Kim, Zachary A. Cooper, Adriano Piris, Dennie T. Frederick, Michal Barzily-Rokni, Ravid Straussman, Rizwan Haq, et al.

  • Open Access

    Supplementary Figures S1-S19 from A Melanoma Cell State Distinction Influences Sensitivity to MAPK Pathway Inhibitors

    by David J. Konieczkowski, Cory M. Johannessen, Omar Abudayyeh, Jong Wook Kim, Zachary A. Cooper, Adriano Piris, Dennie T. Frederick, Michal Barzily-Rokni, Ravid Straussman, Rizwan Haq, et al.

  • Open Access

    Supplementary Tables S1-S2 from A Melanoma Cell State Distinction Influences Sensitivity to MAPK Pathway Inhibitors

    by David J. Konieczkowski, Cory M. Johannessen, Omar Abudayyeh, Jong Wook Kim, Zachary A. Cooper, Adriano Piris, Dennie T. Frederick, Michal Barzily-Rokni, Ravid Straussman, Rizwan Haq, et al.

    PDF file 89K, This file contains a table listing the top 75 genes correlated with RAF-inhibitor sensitivity in BRAFV600E-mutant cell lines as well as a table describing the IHC results summarized in Main Figure 2b and 2c

  • Low‐dose preoperative radiation, resection, and reduced‐field postoperative radiation for soft tissue sarcomas

    by David J. Konieczkowski, Saveli I. Goldberg, Kevin A. Raskin, Santiago Lozano‐Calderon, John T. Mullen, Yen‐Lin Chen, Thomas F. DeLaney

    Background and Objectives: Radiotherapy (RT) enables conservative surgery for soft tissue sarcoma (STS). RT can be delivered either pre‐operatively (PreRT) or postoperatively (PORT), yet in some patients, neither approach is fully satisfactory (e.g., urgent surgery or wound healing risk prevents PreRT, yet PORT alone cannot cover the entire surgical field). We hypothesized that, in such situations, low‐dose PreRT (LD‐PreRT) would decrease the risk of intraoperative tumor seeding and thus permit PORT to a reduced volume (covering the high‐risk tumor bed but not all surgically manipulated tissues).Methods: We identified a single‐institution retrospective cohort of 78 patients treated with LD‐PreRT (10–30 Gy), resection, and PORT between 1980 and 2018.Results: At a median follow‐up of 8.2 years, 8‐year overall survival (OS) was 65.9%, disease‐free survival (DFS) 50.5%, and local control (LC) 76.7%; in 45 patients with extremity/superficial trunk (E/ST) STS, 8‐year LC was 80.9%. Both before and after propensity score adjustment, there were no differences in OS, DFS, or LC between this cohort and a separate cohort of 394 STS (221 E/ST‐STS) patients treated with surgery and PORT alone.Conclusions: In patients for whom neither PreRT nor PORT alone is optimal, LD‐PreRT may prevent intraoperative tumor seeding and enable PORT to a reduced volume while preserving oncologic outcomes.